Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects
Trendline

Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects

What's Happening? Bristol Myers Squibb, a U.S. biopharmaceutical group with a market value of approximately $121.7 billion, is expanding its focus on neuroscience and oncology. The company recently reported initial Phase 3 ADEPT clinical data for KarXT, a treatment for psychosis associated with Alzh
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.